Qilu Pharmaceutical Co., Ltd., commonly known as Qilu Pharma, is a prominent player in the global pharmaceutical industry, headquartered in Jinan, Shandong Province, China. Founded in 1992, the company has established a strong presence in various operational regions, including Asia, Europe, and North America. Specialising in the research, development, and manufacturing of innovative medicines, Qilu Pharma focuses on areas such as oncology, cardiovascular diseases, and central nervous system disorders. Its commitment to quality and innovation has led to the successful launch of several core products, including generic and proprietary drugs that stand out for their efficacy and safety. With a robust market position, Qilu Pharmaceutical has achieved notable milestones, including numerous international certifications and partnerships, solidifying its reputation as a trusted provider in the pharmaceutical landscape.
Qilu Pharmaceutical's reported carbon emissions
Qilu Pharmaceutical, headquartered in China (CN), currently does not report any specific carbon emissions data, as there are no available figures for emissions in kg CO2e. Additionally, the company has not established any documented reduction targets or climate pledges. In the absence of specific emissions data or commitments, it is important to note that Qilu Pharmaceutical's climate strategy and initiatives remain unclear. The company does not appear to inherit any emissions data or climate targets from a parent or related organization, indicating a standalone approach to its environmental impact. As the pharmaceutical industry increasingly focuses on sustainability, Qilu Pharmaceutical may need to consider developing measurable climate commitments and reduction strategies to align with industry standards and expectations.
Unlock Detailed Emission Data
Access structured emission data, company specific emission factors, and source documents.
How Carbon Intensive is Qilu Pharmaceutical's Industry?
How Carbon Intensive is Qilu Pharmaceutical's Location?
Qilu Pharmaceutical's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Qilu Pharmaceutical has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
Usage Policy
You're welcome to quote or reference data from this page, but please include a visible link back to this URL.
Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Where does DitchCarbon data come from?
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Curious To See Your Top Supplier’s Emissions? Book A Demo For A Pilot Project.
Book a demo for your project.